干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎84例疗效观察

IFN α1b Combined with Montelukast Sodium in the Treatment of Children with Asthmatic Bronchitis(84 Cases Reported)

目的:观察干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎的临床疗效。方法:84例小儿喘息性支气管炎患儿按照随机数表方法分为两组各42例,两组在常规治疗的基础上,治疗组加用干扰素α1b 5万U/(kg.d)雾化吸入,并每晚口服孟鲁司特钠4 mg,对照组给予利巴韦林10～15 mg/kg静脉滴注,对比观察两组疗效。结果:治疗组总有效率为92.6%,对照组总有效率为71.4%,两组总有效率比较差异有统计学意义(χ2=10.823,P<0.01),治疗组发热、喘鸣音等症状消失时间明显短于对照组(P<0.01)。结论:干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎安全有效,值得临床推广应用。

Objective： To observe the efficacy of the combined use of IFN α1b and montelukast sodium in the treatment of children with asthmatic bronchitis.Methods： Eighty four children with asthmatic bronchitis were randomly divided into two groups with 42 cases in each group.In addition to symptomatic treatment,IFN α1b 5×104 U/kg,qd and montelukast sodium 4 mg,qn were administered in treatment group,while ribavirin was given at 10~15 mg/kg,qd in control group.Symptoms and signs in two groups were observed.Results： The treatment efficiency was 92.6% in combined treatment group and 71.4% in control group after one week treatment（χ2=10.823,P0.01）.The time for pyretolysis and wheeze disappearance in treatment group was shorter than that in control group（P0.01）.Conclusions： The combined use of IFN α1b and montelukast sodium significantly improves symptoms,shortens the course of disease and increases cure rate without obvious adverse effect in the treatment of children with asthmatic bronchitis.The treatment schedule is worthy of being recommended for clinical application.